294 related articles for article (PubMed ID: 30825009)
1. Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity.
Kato A; Okamoto Y; Okamoto F; Saito M; Miyazono Y; Oshika T
Jpn J Ophthalmol; 2019 May; 63(3):262-268. PubMed ID: 30825009
[TBL] [Abstract][Full Text] [Related]
2. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
3. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
[TBL] [Abstract][Full Text] [Related]
6. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
[TBL] [Abstract][Full Text] [Related]
8. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
[No Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
[TBL] [Abstract][Full Text] [Related]
10. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.
Soheilian M; Karimi S; Montahae T; Nikkhah H; Mosavi SA
Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1705-1712. PubMed ID: 28616715
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
Kimyon S; Mete A
Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
Mintz-Hittner HA; Geloneck MM; Chuang AZ
Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity.
Ozdemir O; Arman A; Tayman C
Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3469-3476. PubMed ID: 34151383
[TBL] [Abstract][Full Text] [Related]
17. Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome.
Ucgul AY; Aktas Z; Ozgur A; Cubuk MO; Hasanreisoglu M; Ozdek S; Gurelik G
J Glaucoma; 2020 Oct; 29(10):981-988. PubMed ID: 32649449
[TBL] [Abstract][Full Text] [Related]
18. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series.
Hillier RJ; Connor AJ; Shafiq AE
Br J Ophthalmol; 2018 Feb; 102(2):260-264. PubMed ID: 28655731
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells.
Park J; Lee M
BMC Ophthalmol; 2018 Jan; 18(1):17. PubMed ID: 29368595
[TBL] [Abstract][Full Text] [Related]
20. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
